Analysis Of Income And Expense [Abstract]

Marinomed Biotech AG - Filing #997033

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	11,276 EUR	—	—	—	11,628 EUR	—
Material income and expense [abstract]
Finance income (cost)	—	—	1,477 EUR	—	—	—	1,550 EUR	—
Expenses by nature [abstract]
Raw materials and consumables used	—	—	7,283 EUR	—	—	—	6,428 EUR	—
Services expense	—	—	1,852 EUR	—	—	—	3,775 EUR	—
Classes of employee benefits expense [abstract]
Employee benefits expense	—	—	4,849 EUR	—	—	—	4,462 EUR	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense	—	—	6,697,000 EUR	—	—	—	6,089,000 EUR	—
Other expenses, by nature	—	—	2,374 EUR	—	—	—	2,073 EUR	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- EUR	- EUR	6,398 EUR	6,398 EUR	- EUR	- EUR	5,891 EUR	5,891 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	6,398 EUR	—	—	—	5,891 EUR	—